Tozasertib

Across CCLE and GDSC cell-line panels, response to Tozasertib is significantly associated with the protein abundance of multiple proteins, with BONE cell lines showing a particularly strong set of associations.

The most reproducible Tozasertib response-associated proteins across cancer lineages are NARS1, RPS4X, and IPO4, each associated with drug response in up to 8 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The scatter plot shows the strongest observed association, Tozasertib response versus NARS1 protein abundance in BONE (Pearson r = 0.66).

Protein abundance biomarkers of Tozasertib response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner protein	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BONE	NARS1 →	+0.583	+1.716	.014	.001	3	8
BLOOD_Lymphoma	RPS4X →	+0.735	+1.382	.007	.002	3	6
KIDNEY	IPO4 →	+0.574	+0.491	.013	.020	3	6
KIDNEY	ZPR1 →	+1.056	+0.498	.025	.036	3	6
CNS	EMC4 →	-1.009	-1.299	.035	.016	3	6
BONE	SPTLC1 →	-0.822	-1.632	.007	<.001	2	7

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Tozasertib response vs NARS1 — BONE

Explore this scatter interactively →